A New Regulatory Epoch: Vaping Navigates the Post-Chevron Landscape

• The Supreme Court’s decisions in Loper Bright and Relentless have dismantled Chevron deference, requiring courts to independently review federal agency actions without automatic deference to their interpretations.
• This shift fundamentally alters the FDA’s regulatory authority over vaping products, particularly challenging the 2016 Deeming Rule and its Premarket Tobacco Application (PMTA) process.
• Numerous industry legal challenges, including the landmark Triton Distribution case heading to the Supreme Court, are poised to redefine the FDA’s scope and the industry’s operational framework.
• The judiciary, exemplified by the Fifth Circuit’s strong criticisms, is increasingly scrutinizing the FDA’s regulatory approach, demanding greater transparency and a balanced consideration of public health and consumer benefit.

A Seismic Shift in Administrative Law: The End of Chevron Deference

The Supreme Court’s recent pronouncements in Loper Bright Enterprises v. Raimondo and Relentless v. Department of Commerce mark a watershed moment in American administrative law. These pivotal rulings have overturned the long-standing principle of Chevron deference, a doctrine established in Chevron v. Natural Resources Defense Council (1984) that for decades permitted courts to defer to federal agencies’ reasonable interpretations of ambiguous statutes. This recalibration mandates that courts now exercise independent judgment, meticulously assessing whether an agency has operated within its statutory authority, rather than automatically acceding to agency expertise. The implications for the regulatory state are profound, ushering in an era of unprecedented judicial scrutiny.

The FDA’s Regulatory Nexus: Vaping in the Post-Chevron Era

For the vaping industry, the dismantling of Chevron deference is nothing short of transformative. The Food and Drug Administration’s (FDA) regulatory authority over vaping products, largely predicated on the 2016 Deeming Rule, has been a source of intense contention. This rule, which expanded the FDA’s jurisdiction to include e-cigarettes and other nicotine products not explicitly covered by the 2009 Family Smoking Prevention and Tobacco Control Act (TCA), has burdened manufacturers with the arduous Premarket Tobacco Application (PMTA) process. The FDA’s overwhelmed system, often leading to widespread Marketing Denial Orders (MDOs) through a “fatal flaw” methodology without thorough individual product reviews, has drawn severe criticism. With Chevron deference no longer a shield, courts are now empowered—and indeed, obligated—to scrutinize the FDA’s actions more critically, potentially leading to rulings that necessitate a more judicious balance between regulatory measures and benefits to adult consumers, all while demanding adherence to transparent processes.

The court criticized the FDA’s review process, calling it arbitrary and capricious.

Battlefronts and Precedents: Industry Challenges to FDA Authority

The vaping industry has long been engaged in a vigorous legal defense of its products, challenging the FDA’s MDOs in courts across the nation. Over 30 companies, including industry stalwarts like Triton Distribution, Juul Labs, and R.J. Reynolds, have initiated legal actions, contending that the agency’s decisions are often arbitrary, unsupported by robust scientific evidence, and fail to acknowledge the critical role vaping plays as a harm-reduction tool for adult smokers. These companies advocate that their products offer a demonstrably safer alternative, crucial for millions seeking to transition away from combustible tobacco. For a comprehensive overview of ongoing legal actions, readers can refer to this constantly updating list of court battles, appeals, and legal actions.

The PMTA Gauntlet and the Fifth Circuit’s Rebuke

Despite federal efforts to tighten regulations, the industry’s resilience is evident in its legal victories. The Fifth Circuit Court of Appeals, in particular, has emerged as a significant check on FDA overreach. Its rulings favoring companies like Triton and Vapetasia have highlighted a growing judicial skepticism towards the FDA’s handling of PMTAs. The court has pointed out instances where the FDA created “unnecessary hurdles not justified by the regulatory framework” and unlawfully denied applications, signaling a clear judicial mandate for the agency to operate within its statutory confines.

The Supreme Court’s Gaze: The Triton Distribution Case

A watershed moment is the Supreme Court’s decision to review the Triton Appeal. This marks the first instance the nation’s highest court will directly address the fairness and legality of the FDA’s vaping regulations. The case stems from Triton Distribution’s successful challenge against an FDA marketing denial order, with the Fifth Circuit having previously criticized the FDA’s review process as “arbitrary and capricious.” The Supreme Court’s decision, anticipated in 2025, could irrevocably shape the future of vaping and nicotine product regulation in the U.S. This pivotal review, alongside the broader implications of the end of Chevron deference, suggests potential shifts in regulatory authority and industry practices that could set new precedents, reshaping the regulatory landscape for years to come.

Balancing Act: Public Health, Innovation, and the Judiciary’s Role

While the industry champions its role in harm reduction, public health advocates voice legitimate concerns, primarily regarding the documented rise in e-cigarette use among young people, especially flavored products. The FDA’s PMTA pathway inherently demands proof that marketing these products is “appropriate for public health,” necessitating a comprehensive evaluation of risks and benefits for the entire population.

The FDA’s targeted denial of many flavored product applications has fueled considerable legal disputes. The aforementioned Fifth U.S. Circuit Court of Appeals has been particularly vocal, directly criticizing the FDA for what it deemed unlawful denials and the imposition of unjustifiable regulatory barriers. This judicial critique serves as a stark reminder of the judiciary’s crucial role in balancing regulatory imperatives with industry interests, ensuring that powerful agencies like the FDA remain tethered to their legal limits. The Biden administration, consequently, faces a complex task: reevaluating its stance on vaping regulations amidst this intensified legal scrutiny, navigating the inherent tension between safeguarding public health and allowing a legitimate industry to innovate and operate under fair legal frameworks.

Conclusion: Charting the Course for Vaping’s Future

The Supreme Court’s resolute decision to end Chevron deference, coupled with its willingness to scrutinize perceived FDA overreach into the vaping industry, heralds a profound transformation in how federal agency regulations will be reviewed. This shift promises to usher in a new era of independent judicial oversight, potentially fostering more balanced, transparent, and legally defensible regulatory processes. As the Supreme Court prepares to hear several key cases, the outcomes are poised to establish new precedents that will define the future trajectory of vaping regulation and broader public health policy. The ongoing discourse underscores the imperative for a nuanced balance between robust regulatory measures that protect future generations from nicotine addiction and equitable industry practices that acknowledge the demonstrated benefits of vaping as a vital smoking cessation tool for adult consumers.